Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Recommendation of “Buy” from Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have received an average rating of “Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $9.50.

QNCX has been the subject of several research analyst reports. D. Boral Capital restated a “buy” rating and set a $12.00 price target on shares of Quince Therapeutics in a research note on Wednesday, February 5th. Brookline Capital Management initiated coverage on Quince Therapeutics in a report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price objective for the company.

Institutional Trading of Quince Therapeutics

A number of institutional investors have recently modified their holdings of QNCX. Geode Capital Management LLC grew its stake in Quince Therapeutics by 24.2% in the 3rd quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock valued at $263,000 after buying an additional 66,170 shares in the last quarter. Scharf Investments LLC bought a new position in shares of Quince Therapeutics in the fourth quarter worth $170,000. Anfield Capital Management LLC purchased a new position in shares of Quince Therapeutics in the fourth quarter valued at $50,000. Virtu Financial LLC bought a new stake in shares of Quince Therapeutics during the 4th quarter valued at $55,000. Finally, Northern Trust Corp lifted its holdings in Quince Therapeutics by 48.5% during the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock worth $94,000 after purchasing an additional 16,501 shares in the last quarter. 30.75% of the stock is currently owned by hedge funds and other institutional investors.

Quince Therapeutics Stock Performance

NASDAQ QNCX opened at $1.38 on Tuesday. The company has a market capitalization of $60.72 million, a PE ratio of -1.11 and a beta of 0.71. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45. The company has a 50-day simple moving average of $1.54 and a 200 day simple moving average of $1.42.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.